I received this in an email today:
Regards
Joe
At some point in the past you used the NexProfiler™ Tool for Breast Cancer. At the time you registered for the treatment decision tool, you indicated that you would be interested in being contacted by NexCura, which operates the NexProfiler Tool for Cancer, to inform you of clinical research being done in the area of breast cancer.
We previously sent you an e-mail about three (3) breast cancer clinical research studies (clinical trials) being conducted in your area that may be of interest to you. The studies are evaluating the safety and effectiveness of an investigational oral drug, GW572016, for the treatment of advanced or metastatic, Stage III or IV, breast cancer in women. If you have already called about these clinical trials, there is no need to call again. However, if you have not called, we wanted to give you another opportunity to participate in these clinical trials.
Below are some of the criteria that you must meet to be eligible for this study:
Female, at least 18 years of age
Diagnosed with Stage III or Stage IV breast cancer
Able to swallow and retain oral medications
Not currently pregnant or nursing.
Additional criteria will be evaluated to determine your eligibility.
All qualified study participants will receive the investigational drug at no cost. The length of study participation is dependent on how each woman and her tumor(s) respond to the study drug(s).
If these studies interest you and you wish to find out if you may be eligible to participate, we invite you to contact Acurian for pre-screening by clicking here
Lapatinib Trial or calling toll free 1-800-563-6118.
About Acurian
Acurian is a company that specializes in education and awareness campaigns for clinical research studies. They are working with the sponsor of these studies to coordinate the pre-screening and referral of women to the research sites for further evaluation and consideration for participation in these breast cancer research studies.
Acurian's Privacy Statement:
Your responses to the pre-screening questions will be kept confidential and will only be shared with the research study doctor's staff to help them determine your final eligibility for this study. This de-identified data may also be shared with the study sponsor, and its representatives, should you be enrolled. Your information will be saved at Acurian only until the study is complete; then it will be destroyed. The decision to participate will be yours alone and you can change your mind at any time.
To see if you are eligible and get more information on the clinical trials, click here:
Clinical Trial Info
or call toll-free 1-800-563-6118.
If you have questions about why you received this e-mail please contact:
NexCura Clinical Trial Services
1725 Westlake Ave. N. Suite 300
Seattle, WA 98109
Email:
clinicaltrials@education.nexcura.com
If you wish to review NexCura's Privacy Statement, visit:
http://www.nexcura.com/nexcura/Nexcura_Privacy.asp
You have received this e-mail as a result of your request for information when you registered with NexCura, Inc. You may unsubscribe from this e-mail notification service at any time by going to the following page:
http://www.nexcura.com/EU.asp?ESubId=D0735...%24%27c%21cb%25
NexCura will not release your e-mail address or other personally identifying information.
Hybrid Mode
